AU2020237097A1 - Sodium fluorescein as a reversal agent for an anti-fluorescein CAR T cells and fluorescein-phospholipid-ethers or profluorescein-phospholipid-ethers - Google Patents

Sodium fluorescein as a reversal agent for an anti-fluorescein CAR T cells and fluorescein-phospholipid-ethers or profluorescein-phospholipid-ethers Download PDF

Info

Publication number
AU2020237097A1
AU2020237097A1 AU2020237097A AU2020237097A AU2020237097A1 AU 2020237097 A1 AU2020237097 A1 AU 2020237097A1 AU 2020237097 A AU2020237097 A AU 2020237097A AU 2020237097 A AU2020237097 A AU 2020237097A AU 2020237097 A1 AU2020237097 A1 AU 2020237097A1
Authority
AU
Australia
Prior art keywords
cell
cells
fluorescein
car
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020237097A
Other languages
English (en)
Other versions
AU2020237097A8 (en
Inventor
Michael C. JENSON
James MATTHAEI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seattle Childrens Hospital
Original Assignee
Seattle Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seattle Childrens Hospital filed Critical Seattle Childrens Hospital
Publication of AU2020237097A1 publication Critical patent/AU2020237097A1/en
Publication of AU2020237097A8 publication Critical patent/AU2020237097A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/4285—Lipids; Lipoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/23—On/off switch
    • A61K2239/24—Dimerizable CARs; CARs with adapter
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/49—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
AU2020237097A 2019-03-13 2020-03-11 Sodium fluorescein as a reversal agent for an anti-fluorescein CAR T cells and fluorescein-phospholipid-ethers or profluorescein-phospholipid-ethers Abandoned AU2020237097A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962818030P 2019-03-13 2019-03-13
US62/818,030 2019-03-13
PCT/US2020/022130 WO2020185917A1 (en) 2019-03-13 2020-03-11 Sodium fluorescein as a reversal agent for an anti-fluorescein car t cells and fluorescein-phospholipid-ethers or profluorescein-phospholipid-ethers

Publications (2)

Publication Number Publication Date
AU2020237097A1 true AU2020237097A1 (en) 2021-11-04
AU2020237097A8 AU2020237097A8 (en) 2022-01-06

Family

ID=72426940

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020237097A Abandoned AU2020237097A1 (en) 2019-03-13 2020-03-11 Sodium fluorescein as a reversal agent for an anti-fluorescein CAR T cells and fluorescein-phospholipid-ethers or profluorescein-phospholipid-ethers

Country Status (6)

Country Link
US (1) US20220125841A1 (https=)
EP (1) EP3937975A4 (https=)
JP (1) JP2022525400A (https=)
AU (1) AU2020237097A1 (https=)
CA (1) CA3140210A1 (https=)
WO (1) WO2020185917A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12312416B2 (en) * 2018-02-06 2025-05-27 Seattle Children's Hospital Fluorescein-specific cars exhibiting optimal t cell function against FL-PLE labelled tumors
CN115210252A (zh) 2020-02-04 2022-10-18 西雅图儿童医院（Dba西雅图儿童研究所） 抗二硝基苯酚的嵌合抗原受体
EP4228660A4 (en) * 2020-10-14 2025-02-26 Georgia Tech Research Corporation Synthetic antigens as chimeric antigen receptor (car) ligands and uses thereof
WO2023224715A1 (en) * 2022-05-19 2023-11-23 Massachusetts Institute Of Technology Car cells targeting an inserted ligand

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4282419A1 (en) * 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
CA2968145C (en) * 2014-11-17 2023-06-27 Cellectar Biosciences, Inc. Phospholipid ether analogs as cancer-targeting drug vehicles
AU2016274989A1 (en) * 2015-06-12 2017-11-02 Immunomedics, Inc. Disease therapy with chimeric antigen receptor (car) constructs and t cells (car-t) or nk cells (car-nk) expressing car constructs
US11408005B2 (en) * 2016-12-12 2022-08-09 Seattle Children's Hospital Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
US11649288B2 (en) * 2017-02-07 2023-05-16 Seattle Children's Hospital Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
WO2018160622A1 (en) * 2017-02-28 2018-09-07 Endocyte, Inc. Compositions and methods for car t cell therapy

Also Published As

Publication number Publication date
JP2022525400A (ja) 2022-05-13
CA3140210A1 (en) 2020-09-17
EP3937975A4 (en) 2023-06-21
WO2020185917A1 (en) 2020-09-17
AU2020237097A8 (en) 2022-01-06
US20220125841A1 (en) 2022-04-28
EP3937975A1 (en) 2022-01-19

Similar Documents

Publication Publication Date Title
CA3176792C (en) Anti-cd3 and anti-bcma bispecific antibodies wth modified heavy chain constant regions
AU2011223547B2 (en) Monoclonal antibodies directed to CD52
US20220125841A1 (en) Sodium fluorescein as a reversal agent for an anti-fluorescein car t cells and fluorescein-phospholipid-ethers or profluorescein-phospholipid-ethers
WO2021222578A1 (en) Multispecific heavy chain antibodies with modified heavy chain constant regions
WO2021000530A1 (zh) 一种双特异性抗体及其制备方法与应用
CN115175694B (zh) 抗baff受体抗体及其用途
KR20230069959A (ko) 다발성 골수종을 치료하기 위한 방법
CA2761885A1 (en) Methods and compositions for treating lupus
JP2022502024A (ja) 抗ヒトｃｄ４５ｒｃ抗体及びその使用
JPWO2020004490A1 (ja) コンドロイチン硫酸プロテオグリカン−５に結合する抗体
CN118974091A (zh) T细胞结合蛋白
US20240239907A1 (en) C-X-C Motif Chemokine Receptor 6 (CXCR6) Binding Molecules, and Methods of Using the Same
CN119060184B (zh) 抗rage抗体及其应用
KR20210119448A (ko) Cd31 경쟁인자(competitor) 및 이의 용도
CN119371542B (zh) 抗rage抗体及其应用
WO2024222863A1 (en) Combination treatment targeting sirpa and claudin 18.2
US20250026841A1 (en) Bispecific antibodies targeting cd137 and uses thereof for anti-cancer immunotherapy
WO2026035616A1 (en) Combinations for the treatment of cancer
WO2022255248A1 (ja) 抗ｃｄ２６抗体と免疫チェックポイント阻害剤との併用療法
JP2024534543A (ja) 腫瘍特異的二重特異性免疫細胞エンゲージャー
WO2025128264A1 (en) Anti-pd-1 monoclonal antibody and methods of use thereof
WO2021258140A1 (en) Cd83 binding protein conjugates for treating lymphoma
TW202602924A (zh) 抗ccr8抗體之醫藥配製物
HK40115334A (zh) 肿瘤特异性双特异性免疫细胞接合剂

Legal Events

Date Code Title Description
TH Corrigenda

Free format text: IN VOL 35 , NO 44 , PAGE(S) 8630 UNDER THE HEADING PCT APPLICATIONS THAT HAVE ENTERED THE NATIONAL PHASE - NAME INDEX UNDER THE NAME SEATTLE CHILDREN'S HOSPITAL (DBA SEATTLE CHILDREN'S RESEARCH INSTITUTE), APPLICATION NO. 2020237097, UNDER INID (54) CORRECT THE TITLE TO READ SODIUM FLUORESCEIN AS A REVERSAL AGENT FOR AN ANTI-FLUORESCEIN CAR T CELLS AND FLUORESCEIN-PHOSPHOLIPID-ETHERS OR PROFLUORESCEIN-PHOSPHOLIPID-ETHERS

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application